These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 12941579)

  • 21. Natalizumab for relapsing remitting multiple sclerosis.
    Pucci E; Giuliani G; Solari A; Simi S; Minozzi S; Di Pietrantonj C; Galea I
    Cochrane Database Syst Rev; 2011 Oct; (10):CD007621. PubMed ID: 21975773
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current disease-modifying treatment of multiple sclerosis.
    Derwenskus J
    Mt Sinai J Med; 2011; 78(2):161-75. PubMed ID: 21425262
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of multiple sclerosis: role of natalizumab.
    Comi G
    Neurol Sci; 2009 Oct; 30 Suppl 2():S155-8. PubMed ID: 19882365
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Parenteral Treatment of Multiple Sclerosis: The Advent of Monoclonal Antibodies.
    Singer BA
    Semin Neurol; 2016 Apr; 36(2):140-7. PubMed ID: 27116720
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Escalating immunomodulatory therapy of multiple sclerosis. Update (September 2006)].
    ; Rieckmann P
    Nervenarzt; 2006 Dec; 77(12):1506-18. PubMed ID: 17136556
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Recent advances in the pathogenesis and immunotherapy of multiple sclerosis].
    Gold R; Rieckmann P
    Nervenarzt; 2007 Sep; 78 Suppl 1():15-24; quiz 25. PubMed ID: 17668159
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alemtuzumab as rescue therapy in a cohort of 16 aggressive multiple sclerosis patients previously treated by Mitoxantrone: an observational study.
    Le Page E; Deburghgraeve V; Lester MA; Cardiet I; Leray E; Edan G
    J Neurol; 2015; 262(4):1024-34. PubMed ID: 25701008
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Choice of early and escalation treatment options for multiple sclerosis].
    Linker RA; Kieseier BC
    Nervenarzt; 2008 Oct; 79(10):1123-4,1126-8,1130-2 passim. PubMed ID: 18806985
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiple sclerosis. Part 2: ophthalmic issues in MS therapy.
    Pula JH; Javed A
    Curr Opin Ophthalmol; 2009 Nov; 20(6):476-81. PubMed ID: 19816177
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction or escalation therapy for patients with multiple sclerosis?
    Le Page E; Edan G
    Rev Neurol (Paris); 2018 Jun; 174(6):449-457. PubMed ID: 29799415
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current and future role of interferon beta in the therapy of multiple sclerosis.
    Farrell RA; Giovannoni G
    J Interferon Cytokine Res; 2010 Oct; 30(10):715-26. PubMed ID: 20874249
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Utilization, cost trends, and member cost-share for self-injectable multiple sclerosis drugs--pharmacy and medical benefit spending from 2004 through 2007.
    Kunze AM; Gunderson BW; Gleason PP; Heaton AH; Johnson SV
    J Manag Care Pharm; 2007; 13(9):799-806. PubMed ID: 18062731
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug. A critical evaluation based upon evidence based parameters and published systematic reviews.
    Clerico M; Rivoiro C; Contessa G; Viglietti D; Durelli L
    Clin Neurol Neurosurg; 2008 Nov; 110(9):878-85. PubMed ID: 18164542
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emerging monoclonal antibody therapies for multiple sclerosis.
    Cree B
    Neurologist; 2006 Jul; 12(4):171-8. PubMed ID: 16832236
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mitoxantrone in the treatment of multiple sclerosis.
    Morrissey SP; Le Page E; Edan G
    Int MS J; 2005 Nov; 12(3):74-87. PubMed ID: 16417821
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical management of multiple sclerosis and neuromyelitis optica with therapeutic monoclonal antibodies: approved therapies and emerging candidates.
    Dubey D; Kieseier BC; Hartung HP; Hemmer B; Miller-Little WA; Stuve O
    Expert Rev Clin Immunol; 2015 Jan; 11(1):93-108. PubMed ID: 25495182
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alemtuzumab and multiple sclerosis: therapeutic application.
    Minagar A; Alexander JS; Sahraian MA; Zivadinov R
    Expert Opin Biol Ther; 2010 Mar; 10(3):421-9. PubMed ID: 20095876
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Buzz around Campath proof-of-concept trial in MS.
    Osborne R
    Nat Biotechnol; 2009 Jan; 27(1):6-8. PubMed ID: 19131976
    [No Abstract]   [Full Text] [Related]  

  • 39. [Disease modifying therapies in multiple sclerosis].
    Fukaura H
    Nihon Rinsho; 2014 Nov; 72(11):2015-22. PubMed ID: 25518387
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Teriflunomide for multiple sclerosis.
    He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.